350 related articles for article (PubMed ID: 33768301)
1. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.
Mielczarek Ł; Brodziak A; Sobczuk P; Kawecki M; Cudnoch-Jędrzejewska A; Czarnecka AM
Cancer Chemother Pharmacol; 2021 Jun; 87(6):723-742. PubMed ID: 33768301
[TBL] [Abstract][Full Text] [Related]
2. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
Jaimes EA
Semin Nephrol; 2020 Jan; 40(1):49-58. PubMed ID: 32130966
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Tyrosine Kinase Inhibitor
Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
[TBL] [Abstract][Full Text] [Related]
4. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
5. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
Parikh M; Lara PN
Annu Rev Med; 2018 Jan; 69():209-221. PubMed ID: 29144835
[TBL] [Abstract][Full Text] [Related]
6. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
8. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.
González-Larriba JL; Maroto P; Durán I; Lambea J; Flores L; Castellano D;
Expert Rev Anticancer Ther; 2017 Mar; 17(3):217-226. PubMed ID: 28105863
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase inhibitors in renal cell carcinoma.
Daste A; Grellety T; Gross-Goupil M; Ravaud A
Expert Opin Pharmacother; 2014 Feb; 15(3):337-51. PubMed ID: 24328606
[TBL] [Abstract][Full Text] [Related]
10. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.
Boers-Doets CB; Epstein JB; Raber-Durlacher JE; Ouwerkerk J; Logan RM; Brakenhoff JA; Lacouture ME; Gelderblom H
Oncologist; 2012; 17(1):135-44. PubMed ID: 22207567
[TBL] [Abstract][Full Text] [Related]
11. Toxicities of targeted agents in advanced renal cell carcinoma.
Patel P; Srinivas S
Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
[TBL] [Abstract][Full Text] [Related]
12. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
Gulati S; Vaishampayan U
Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
[TBL] [Abstract][Full Text] [Related]
13. Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis.
Rizzo A; Mollica V; Santoni M; Massari F
Expert Rev Gastroenterol Hepatol; 2021 Oct; 15(10):1225-1232. PubMed ID: 34167420
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
15. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
16. Selected toxicities of targeted therapies: presentation and management.
Kollmannsberger C; Mitchell T
Semin Oncol; 2013 Aug; 40(4):499-510. PubMed ID: 23972714
[TBL] [Abstract][Full Text] [Related]
17. Sequencing therapy in metastatic renal cell cancer.
Escudier B; Gore M
Semin Oncol; 2013 Aug; 40(4):465-71. PubMed ID: 23972710
[TBL] [Abstract][Full Text] [Related]
18. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
20. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
